Luminex Corporation has submitted the ARIES® MRSA Assay to the U.S. Food and Drug Administration (FDA) for clearance on Friday, June 28, 2019. The assay is a real-time, quantitative polymerase chain reaction (qPCR)-based, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.

The Luminex ARIES^® System is a sample to answer, real-time system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory. The system already offers six FDA and seven CE-IVD cleared assays, as well as the ability to run laboratory developed tests.